Delcath Systems
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
66 Queensbury Ave, Queensbury, New York,...Phone Number
(917) 902-6455Website
www.delcath.comRevenue
$90.4 MillionStock Symbol
DCTHIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, NY.Explore more
Delcath Systems Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Delcath Systems your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Delcath Systems launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Delcath Systems
Earning: See what the market has to say on Delcath Systems recently announced quarterly report
Check out if Delcath Systems is spiking on competitors!
Delcath Systems, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Delcath Systems had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Delcath Systems has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Delcath Systems has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Delcath Systems
Compare insights from companies similar to Delcath Systems, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Delcath Systems is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Delcath Systems is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Delcath Systems.
Delcath Systems financials insights
Gather financial insights about Delcath Systems, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2000
Stock Offering
$7.2M
2023
Other Financing Round
$85M
2024
Series E
$16.3M
Delcath Systems Tech Stack
A closer look at the technologies used by Delcath Systems
See more technologies
Most Recent Scoops
Hiring Plans
Delcath Systems has more open roles in Operations than it has had at any time in the past 12 months. Areas of expertise include: Warehouse Operations, Shipment Preparation, and Materials Transport.
Hiring Plans
Person-Based
Executive Moves, Earnings, Finance
Hiring Plans
Delcath Systems is hiring in Legal for the first time in 12 months with an increased focus that include Compliance Implementation, and FDA Regulations, and experience with Regulatory Requirements.
Hiring Plans
Hiring Plans
Delcath Systems has more open roles in Information Technology than it has had at any time in the past 12 months. Technologies mentioned include: R, Linux, TIBCO Spotfire, and Python.
Hiring Plans
Hiring Plans
Hiring Plans
Delcath Systems News & Media
Delcath Systems publishes results from subgroup analyses of FOCUS study
Delcath Systems (DCTH) announced the publication of results from subgroup analyses of the phase 3 FOCUS study. The publication was published in the Journal of Cancer Research and Clinical Oncology. The analysis assessed efficacy and safety in subgroups of patients treated with Delcath’s Hepzato Kit, a drug/device combination for liver-directed treatment of mUM patients. The Hepzato Kit is currently the only liver-directed treatment to be approved by the FDA for patients with unresectable mUM. ThHere’s What Hit Delcath Systems (DCTH) in Q3
Riverwater Partners, an investment management company, released its “Micro Opportunities Strategy” Q3 2025 investor letter. A copy of the letter can be downloaded here. The strategy reported solid absolute returns in the quarter but lagged the benchmark as it did not keep pace with the strong rally. The strategy continues to focus on quality companies […]Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
Delcath Systems, Inc. an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors has authorized a share repurchase program under which Delcath may repurchase up to $25 million of its outstanding shares of common stock from time to time, subject to market conditions. The repurchase program does not have an expiration date. ...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Delcath Systems
Sign Up For FreeTo access detailed company insights
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic C... Read More
